Literature DB >> 16598408

Unsuccessful intraventricular pentosan polysulphate treatment of variant Creutzfeldt-Jakob disease.

I R Whittle1, R S G Knight, R G Will.   

Abstract

Pentosan polysulphate, delivered by chronic intraventricular infusion, has been proposed as a potential therapy for human prion disease. The first treated patient is still alive several years after treatment started. Here we describe in detail a case of variant Creutzfeldt-Jakob disease in which this treatment was started at a relatively early stage but had no definite clinical benefit. The patient died from disease progression 16 months after diagnosis and 5 months after pentosan polysulphate treatment was commenced.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16598408     DOI: 10.1007/s00701-006-0772-y

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  16 in total

Review 1.  Sulfated glycosaminoglycans in protein aggregation diseases.

Authors:  Kazuchika Nishitsuji; Kenji Uchimura
Journal:  Glycoconj J       Date:  2017-04-11       Impact factor: 2.916

Review 2.  Rapidly progressive dementias and the treatment of human prion diseases.

Authors:  Brian S Appleby; Constantine G Lyketsos
Journal:  Expert Opin Pharmacother       Date:  2010-11-23       Impact factor: 3.889

3.  Diphenylpyrazole-derived compounds increase survival time of mice after prion infection.

Authors:  Fabienne Leidel; Martin Eiden; Markus Geissen; Hans A Kretzschmar; Armin Giese; Thomas Hirschberger; Paul Tavan; Hermann M Schätzl; Martin H Groschup
Journal:  Antimicrob Agents Chemother       Date:  2011-07-11       Impact factor: 5.191

4.  Long term survival in a patient with variant Creutzfeldt-Jakob disease treated with intraventricular pentosan polysulphate.

Authors:  A Parry; I Baker; R Stacey; S Wimalaratna
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-02-21       Impact factor: 10.154

5.  Calcineurin inhibition at the clinical phase of prion disease reduces neurodegeneration, improves behavioral alterations and increases animal survival.

Authors:  Abhisek Mukherjee; Diego Morales-Scheihing; Dennisse Gonzalez-Romero; Kristi Green; Giulio Taglialatela; Claudio Soto
Journal:  PLoS Pathog       Date:  2010-10-07       Impact factor: 6.823

6.  Antiprion activity of cholesterol esterification modulators: a comparative study using ex vivo sheep fibroblasts and lymphocytes and mouse neuroblastoma cell lines.

Authors:  Alessandra Pani; Claudia Norfo; Claudia Abete; Claudia Mulas; Marirosa Putzolu; Sergio Laconi; Christina Doriana Orrù; M Dolores Cannas; Sarah Vascellari; Paolo La Colla; Sandra Dessì
Journal:  Antimicrob Agents Chemother       Date:  2007-08-20       Impact factor: 5.191

7.  Mechanistic insights into the cure of prion disease by novel antiprion compounds.

Authors:  Sarah Webb; Tamuna Lekishvili; Corinna Loeschner; Shane Sellarajah; Frances Prelli; Thomas Wisniewski; Ian H Gilbert; David R Brown
Journal:  J Virol       Date:  2007-07-25       Impact factor: 5.103

8.  Toxic effects of intracerebral PrP antibody administration during the course of BSE infection in mice.

Authors:  Maxime Lefebvre-Roque; Elisabeth Kremmer; Sabine Gilch; Wen-Quan Zou; Cécile Féraudet; Chantal Mourton Gilles; Nicole Salès; Jacques Grassi; Pierluigi Gambetti; Thierry Baron; Hermann Schätzl; Corinne Ida Lasmézas
Journal:  Prion       Date:  2007-07-15       Impact factor: 3.931

9.  Heparin binding confers prion stability and impairs its aggregation.

Authors:  Tuane C R G Vieira; Yraima Cordeiro; Byron Caughey; Jerson L Silva
Journal:  FASEB J       Date:  2014-03-19       Impact factor: 5.191

10.  Effective gene therapy in a mouse model of prion diseases.

Authors:  Karine Toupet; Valérie Compan; Carole Crozet; Chantal Mourton-Gilles; Nadine Mestre-Francés; Françoise Ibos; Pierre Corbeau; Jean-Michel Verdier; Véronique Perrier
Journal:  PLoS One       Date:  2008-07-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.